The global care patient monitoring products, required to enhance patient care and clinical performance in the global intensive care unit (ICU), are witnessing a growing demand in t...
Future market insights report that the global critical Care Patient Monitoring Products market is expected to witness a steady growth. The growth of overall health care sector during the forecast period is expected to influence the growth of global critical care patient monitoring products market. Technavio's analysts forecast the global critical care therapeutics market to grow at a CAGR of 3.62 percent during the period 2017-2021. The top vendors are Kedrion Biopharma, Octapharma, Shire, Abeona Therapeutics, ADMA Biologics, Albumedix, Armetheon, Asklepios BioPharmaceutical, and many more. The market is segmented by geography (the Americas, APAC and EMEA), by drug class (albumin market, prothrombin complex concentrates market, antithrombin concentrates market, factor XIII concentrates market, fibrinogen concentrates market) and by application (DVT, Pulmonary embolism (PE), Acute coronary syndrome, Atrial fibrillation, Hemodialysis, Coronary angioplasty, Surgeries). According to future market insights the major driving factors for global critical care patient monitoring products market are population aging and an increase in rate of chronic diseases. Moreover, increase in number of health care facilities across the globe is expected to fuel the growth of global critical care patient monitoring products. Also, Increase in lifestyle influenced diseases such as coronary heart diseases, along with the growing affluence has resulted in a steady growth in demand for critical care patient monitoring products. On the flip side, the high cost of these critical care products can act as an impediment to the growth of global critical care patient monitoring products market. Technavio's analysts observe a trend of increased development of recombinant products due to a growing preference for marketed products over alternative treatment options. One driver in the market is increasing surgical procedures. The increasing surgical procedures such as hip and knee replacements will increase the risk of DVT, thereby driving the market growth. Surgeries often result in long periods of immobility, thus increasing the chances of developing DVT due to reduced blood flow. It is reported that over a million Americans undergo joint replacement surgeries every year. Individuals undergoing knee replacement and hip replacement surgeries have an increased likelihood of developing DVT. There is a trend in the establishment of plasma fractionation facilities in emerging economies by global players. Plasma fractionation in developed countries is proving very costly, so there has been a growing focus of vendors to tap the emerging economies such as the Middle East, Africa, China, and India. These geographies become a favorite due to the easy availability of skilled personnel, raw materials, cheap labor and land, a larger volume of available plasma due to large population base, and supportive government regulations. However, currently the presence of plasma fractionation facilities is very much limited to China within emerging countries, but in future, the incentives listed above should be driving the vendors to establish more facilities in these regions. For instance, in 2010, Celestial Biologicals, an associate company of Intas Biopharmaceuticals, in collaboration with GE Healthcare started a plasma fractionation facility in India. Going forward, to benefit from the unmet demand in the emerging markets and the incentives of opening such facilities in the region, would drive global players to open number of such facilities in the region